IgG glycan patterns are associated with type 2 diabetes in independent European populations

https://doi.org/10.1016/j.bbagen.2017.06.020Get rights and content

Highlights

  • Several IgG glycans firmly associate with type 2 diabetes.

  • Associated IgG glycans in T2D reflect a pro-inflammatory and biologically aged state.

  • These associations may yield insights in type 2 diabetes pathophysiology.

Abstract

Background

Type 2 diabetes results from interplay between genetic and acquired factors. Glycans on proteins reflect genetic, metabolic and environmental factors. However, associations of IgG glycans with type 2 diabetes have not been described. We compared IgG N-glycan patterns in type 2 diabetes with healthy subjects.

Methods

In the DiaGene study, a population-based case-control study, (1886 cases and 854 controls) 58 IgG glycan traits were analyzed. Findings were replicated in the population-based CROATIA-Korcula-CROATIA-Vis-ORCADES studies (162 cases and 3162 controls), and meta-analyzed. AUCs of ROC-curves were calculated using 10-fold cross-validation for clinical characteristics, IgG glycans and their combination.

Results

After correction for extensive clinical covariates, 5 IgG glycans and 13 derived traits significantly associated with type 2 diabetes in meta-analysis (after Bonferroni correction). Adding IgG glycans to age and sex increased the AUC from 0.542 to 0.734. Adding them to the extensive model did not substantially improve the AUC. The AUC for IgG glycans alone was 0.729.

Conclusions

Several IgG glycans and traits firmly associate with type 2 diabetes, reflecting a pro-inflammatory and biologically-aged state. IgG glycans showed limited improvement of AUCs. However, IgG glycans showed good prediction alone, indicating they may capture information of combined covariates. The associations found may yield insights in type 2 diabetes pathophysiology.

General significance

This work shows that IgG glycomic changes have biomarker potential and may yield important insights into pathophysiology of complex public health diseases, illustrated here for the first time in type 2 diabetes.

Introduction

Type 2 diabetes is an extremely challenging health issue in the 21st century [1]. It is a multifactorial disease, resulting from intricate interplay between environmental and genetic factors. Although many environmental and genetic risk factors have been identified, the underlying mechanisms of the disease remain largely unknown.

Genetic factors identified so far explain up to 5–10% of disease risk [2]. It is likely that epigenetic and posttranscriptional modifications play a substantial role in disease pathophysiology. Glycosylation of proteins is one of the most common posttranslational modifications. N-glycans are present on most proteins and are generated through interplays between hundreds of enzymes [3], [4]. They play structural, functional, and regulatory roles and reflect genetic, metabolic, and environmental factors [3]. These unique qualities raise interest for the role and use of N-glycans in complex disease such as type 2 diabetes. Total N-glycomic changes have been reported once in a relatively large type 2 diabetes population and showed significant changes. However, total N-glycomic changes do not inform us on the exact underlying proteins and processes involved and results are influenced by the relative abundance of proteins in the circulation.

Type 2 diabetes is characterized by a pro-inflammatory state and elevated levels of inflammatory markers, such as C-reactive protein and interleukin-6, that have been associated with risk of developing type 2 diabetes [5]. IgG N-glycome changes have been linked to clinical risk factors for type 2 diabetes, such as age, BMI, smoking, and dyslipidemia [6], [7], [8], [9]. IgG is a tetramer protein complex consisting of Fc and Fab regions. IgG glycosylation is particularly interesting, as N-glycans attached to the Fc part of IgG can modulate and switch its function from pro- to anti-inflammatory and vice versa [3], [10], [11]. However, IgG N-glycosylation patterns in type 2 diabetes compared to the non-diabetic state have not been described in current literature. Knowledge on specific IgG N-glycosylation profiles in type 2 diabetes could shed light on underlying inflammatory pathophysiological processes and on drug target and biomarker potential.

We hypothesized that characteristic IgG N-glycan profiles are present in type 2 diabetes. In this study, we investigated the association of IgG N-glycan profiles with type 2 diabetes in a large population-based case control cohort, followed by replication in independent European samples. Moreover, we evaluate the AUC under the Receiver Operator Characteristic (ROC) curves for models including clinical characteristics, IgG glycans, and both.

Section snippets

Discovery cohort

The discovery cohort was the DiaGene study. Characteristics of the DiaGene population have been described elsewhere [12]. Briefly, the DiaGene study is a case-control cohort collected in and around the city of Eindhoven, the Netherlands. All hospitals in this area participated, as well as the center for primary care diagnostics. Type 2 diabetes was diagnosed according the ADA and WHO criteria [13], [14]. Patients with other types of diabetes, diabetes secondary to Cushing's syndrome or to

Cohort characteristics

Characteristics of the cohorts are shown in Table 1. In the DiaGene study, patients with type 2 diabetes were more often male (53.7 vs. 40.2% for cases and controls, respectively), had higher BMI and creatinine levels, lower HDL-cholesterol and non-HDL cholesterol levels, and were more often smokers than healthy controls. In the replication cohort, cases were older (66.6 vs. 54.5 years), had a lower HDL-cholesterol, and higher BMI and creatinine.

Clinical traits associated with type 2 diabetes or N-glycosylation

Correlations of clinical traits associated with

Discussion

In the present study, we are the first to describe the association and predictive potential of IgG N-glycans in type 2 diabetes versus healthy individuals in a large case-control study. We have found significant and replicated associations for GP6, GP8, GP9, GP10, and GP11 and several derived IgG glycan traits associated with decreased galactosylation and sialyation, an increase in fucosylated structures with bisecting GlcNAc and a decrease in fucosylated structures without bisecting GlcNAc.

Transparency Document

Transparency document.

Acknowledgements

Funding

MH was supported by the Erasmus MC fellowship. Glycan analysis was supported in part by FP7 projects HighGlycan (contract #278535), MIMOmics (contract #305280), MLPM (contract #316861), HTP-GlycoMet (contract #324400) and RegPot Integra-Life (contract #315997) from the European Commission and the HRZZ grant #7769.

Duality of interest

RL, MS, IR, HC, CH, JW, AL, OG, ES, MH declare no conflicts of interest.

FA is a founder and co-owner of Pharmatics Limited. Pharmatics declares no conflicts

References (50)

  • E. Hertle et al.

    The complement system in human cardiometabolic disease

    Mol. Immunol.

    (2014)
  • M. Holland et al.

    Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis

    Biochim. Biophys. Acta

    (2006)
  • WHO

    Diabetes mellitus

  • A.P. Morris et al.

    Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes

    Nat. Genet.

    (2012)
  • G. Lauc et al.

    Complex genetic regulation of protein glycosylation

    Mol. BioSyst.

    (2010)
  • X. Wang et al.

    Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis

    Diabetes Care

    (2013)
  • J. Kristic et al.

    Glycans are a novel biomarker of chronological and biological ages

    J. Gerontol. A Biol. Sci. Med. Sci.

    (2014)
  • A. Knezevic et al.

    Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans

    Glycobiology

    (2010)
  • Y. Wang et al.

    The association between glycosylation of immunoglobulin G and hypertension: a multiple ethnic cross-sectional study

    Medicine (Baltimore)

    (2016)
  • R.M. Anthony et al.

    Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc

    Science

    (2008)
  • Y. Kaneko et al.

    Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation

    Science

    (2006)
  • B.F. Voight et al.

    Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis

    Nat. Genet.

    (2010)
  • K.G. Alberti et al.

    Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

    Diabet. Med.

    (1998)
  • A. American Diabetes

    Diagnosis and classification of diabetes mellitus

    Diabetes Care

    (2011)
  • I. Rudan et al.

    Genetic epidemiological studies of eastern Adriatic Island isolates, Croatia: objective and strategies

    Coll. Antropol.

    (1999)
  • Cited by (0)

    1

    These authors contributed equally.

    View full text